What is Eversight?
Founded in 1947, Eversight has evolved into a cornerstone of the international ophthalmology community. Operating as a full-service eye bank and research partner, the organization facilitates the recovery, evaluation, and distribution of human eye tissue for life-changing transplants. Beyond its core banking functions, Eversight distinguishes itself through the Eversight Center for Vision and Eye Banking Research in Cleveland. This facility serves as a hub for scientific inquiry, providing essential biofluids and tissue for clinical studies while fostering collaborations with academic medical centers and surgeons worldwide. By integrating humanitarian aid with cutting-edge R&D, Eversight maintains a unique market position as both a service provider and a catalyst for medical innovation in the field of vision health.
How much funding has Eversight raised?
Eversight has raised a total of $25.2M across 3 funding rounds:
Series A
$9.7M
Private Equity
$14.5M
Private Equity
$1M
Series A (2014): $9.7M with participation from Emergence Capital Partners
Private Equity (2016): $14.5M led by Emergence Capital Partners and Sutter Hill Ventures
Private Equity (2016): $999K, investors not publicly disclosed
Key Investors in Eversight
Emergence Capital Partners
Emergence is a premier venture capital firm specializing in early-stage enterprise companies, dedicated to partnering with organizations that fundamentally transform how the world operates.
Sutter Hill Ventures
Headquartered in Palo Alto, Sutter Hill Ventures is a veteran investment firm focused on financing technology-based startups and providing strategic guidance to build market-leading enterprises.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the organization's long-term mission and operational objectives.
What's next for Eversight?
Looking ahead, Eversight is positioned to leverage its established infrastructure to scale its global initiatives. The organization's strategic roadmap emphasizes the development of sustainable eye banking models in underserved regions, coupled with intensive clinical training for international surgical teams. By continuing to bridge the gap between donation and transplantation, Eversight aims to mitigate the impact of corneal blindness, which currently affects millions globally. Future efforts will likely focus on deepening its research partnerships and expanding its technological capabilities to ensure that the healing power of donation remains accessible, efficient, and scientifically rigorous on a global scale.
See full Eversight company page
